Literature DB >> 18817637

Behçet's disease: recent advances in early diagnosis and effective treatment.

Kenneth T Calamia1, Phaedon G Kaklamanis.   

Abstract

Behçet's disease (BD) is a chronic, multisystem, inflammatory disorder that is classified among the systemic vasculitidies. Its cause has yet to be determined, but genetic and environmental factors and immune dysregulation are thought to play a role in its pathogenesis. The diagnosis of the disease and recognition and separation from disorders that may mimic BD may be difficult, especially in areas where the disease is uncommon. Certainty as to the best treatments for the various manifestations of BD is often unclear due to limited randomized controlled trials. However, existing consensus statements and expert opinions should help to guide therapy. This review examines important recent contributions to help the clinician more readily recognize patients with the disease and institute appropriate care.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18817637     DOI: 10.1007/s11926-008-0057-y

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  44 in total

1.  Evidence for linkage of the HLA-B locus in Behçet's disease, obtained using the transmission disequilibrium test.

Authors:  A Gül; A H Hajeer; J Worthington; J H Barrett; W E Ollier; A J Silman
Journal:  Arthritis Rheum       Date:  2001-01

Review 2.  An update on Behçet's disease.

Authors:  A Kalayciyan; Cc Zouboulis
Journal:  J Eur Acad Dermatol Venereol       Date:  2007-01       Impact factor: 6.166

Review 3.  Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature.

Authors:  Nicolò Pipitone; Ignazio Olivieri; Angela Padula; Salvatore D'angelo; Angelo Nigro; Giulio Zuccoli; Luigi Boiardi; Carlo Salvarani
Journal:  Arthritis Rheum       Date:  2008-02-15

Review 4.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

5.  Anti-Saccharomyces cerevisiae antibodies in Behçet's disease--a familial study.

Authors:  A Monselise; A Weinberger; Y Monselise; A Fraser; J Sulkes; I Krause
Journal:  Clin Exp Rheumatol       Date:  2006 Sep-Oct       Impact factor: 4.473

6.  Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.

Authors:  Melike Melikoglu; Izzet Fresko; Cem Mat; Yilmaz Ozyazgan; Feride Gogus; Sebahattin Yurdakul; Vedat Hamuryudan; Hasan Yazici
Journal:  J Rheumatol       Date:  2005-01       Impact factor: 4.666

Review 7.  The use of interferon alpha in Behçet disease: review of the literature.

Authors:  Ina Kötter; Ilhan Günaydin; Manfred Zierhut; Nicole Stübiger
Journal:  Semin Arthritis Rheum       Date:  2004-04       Impact factor: 5.532

8.  MEFV mutations are increased in Behçet's disease (BD) and are associated with vascular involvement.

Authors:  P Atagunduz; T Ergun; H Direskeneli
Journal:  Clin Exp Rheumatol       Date:  2003 Jul-Aug       Impact factor: 4.473

9.  Longterm visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-alpha-2a.

Authors:  Lothar Krause; Andreas Altenburg; Uwe Pleyer; Anne-Katrin Köhler; Christos C Zouboulis; Michael H Foerster
Journal:  J Rheumatol       Date:  2008-04-15       Impact factor: 4.666

10.  Treatment of venous thrombosis associated with Behcet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation.

Authors:  Joong Kyong Ahn; You Sun Lee; Chan Hong Jeon; Eun-Mi Koh; Hoon-Suk Cha
Journal:  Clin Rheumatol       Date:  2007-07-17       Impact factor: 2.980

View more
  5 in total

Review 1.  Evaluation of current therapeutic strategies in Behçet's disease.

Authors:  Iliana Alexoudi; Violetta Kapsimali; Aristides Vaiopoulos; Meletios Kanakis; George Vaiopoulos
Journal:  Clin Rheumatol       Date:  2010-09-15       Impact factor: 2.980

2.  Geographical variations in ocular and extra-ocular manifestations in Behçet's disease.

Authors:  Farhad Shahram; Marthe T Mæhlen; Massoomeh Akhlaghi; Fereydoun Davatchi; Yaping Joyce Liao; Cornelia M Weyand
Journal:  Eur J Rheumatol       Date:  2019-07-19

3.  Diagnostic value of pathergy test in Behcet's disease according to the change of incidence over the time.

Authors:  Fereydoun Davatchi; Cheyda Chams-Davatchi; Zahra Ghodsi; Farhad Shahram; Abdolhadi Nadji; Hormoz Shams; Massoomeh Akhlaghi; Roghieh Larimi; Bahar Sadeghi-Abdolahi
Journal:  Clin Rheumatol       Date:  2011-03-02       Impact factor: 2.980

Review 4.  Longitudinal extensive transverse myelitis--it's not all neuromyelitis optica.

Authors:  Corinna Trebst; Peter Raab; Elke Verena Voss; Paulus Rommer; Mazen Abu-Mugheisib; Uwe K Zettl; Martin Stangel
Journal:  Nat Rev Neurol       Date:  2011-11-01       Impact factor: 42.937

5.  Behçet's Disease as a Model of Venous Thrombosis.

Authors:  Micaela La Regina; Armen Yuri Gasparyan; Francesco Orlandini; Domenico Prisco
Journal:  Open Cardiovasc Med J       Date:  2010-02-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.